Although high-sensitivity C-reactive protein (hs-CRP) has been used to predict the risk of adverse cardiac events in patients with coronary artery disease (CAD) after percutaneous coronary interventions (PCIs), little is known about the association between hs-CRP and long-term outcomes in patients with preserved renal function.
T he contribution of inflammation to the pathobiology of atherosclerosis is well characterized. 1, 2) In addition, elevated serum levels of C-reactive protein (CRP), which is a biomarker of inflammation, has been shown to be present among subjects at risk for future atherothrombotic diseases in the coronary artery, independent of the established cardiovascular risk factors. 2, 3) Recently, patients with stage III-V chronic kidney disease (CKD) were shown to be at risk for kidney disease progression and development of end-stage renal disease. Moreover, these patients appear to be at a relatively high risk for developing cardiovascular diseases, along with their associated morbidity and mortality. 4, 5) The predictive value of CRP in patients with underlying CKD has previously been reported. In particular, high serum levels of CRP were found to be an independent risk factor for cardiovascular mortality in a few cohorts and in the participants of the Modification of Diet in Renal Disease (MDRD) study. [6] [7] [8] However, to our knowl-edge, there are no available data or hypotheses on the comparable relationship between CRP and the risk factors in cases with preserved renal function. Among these patients, serum high-sensitivity C-reactive protein (hs-CRP) levels are much lower compared with patients with CKD, and it is still unclear whether hs-CRP is a useful marker for them. In the present study, therefore, the prognostic value of preprocedural serum high-sensitivity CRP (hs-CRP) levels for long-term clinical outcomes was evaluated in patients with coronary artery disease (CAD) and preserved renal function.
Methods

Study population and data collection:
The present study was a single-center, observational, retrospective cohort study. Among consecutive patients with CAD who underwent their first percutaneous coronary intervention (PCI) at Juntendo University Hospital between 2000 and 2011, Figure 1 . Flow chart of the study inclusion. Of the 2,092 patients who underwent PCIs, preprocedural hs-CRP values were available for only 1,694 of them. Patients with CKD (n = 541) were excluded. The patients were then divided into three groups according to the preprocedural hs-CRP level (< 0.05, 0.05-0.17, and > 0.17 mg/dL). CKD indicates chronic kidney disease; hs-CRP, high-sensitivity C-reactive protein; and PCI, percutaneous coronary intervention.
we included only those with available data on preprocedural hs-CRP. We excluded patients with CKD, which was defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/minute/1.73 m 2 , as calculated by the MDRD equation, which was modified with a Japanese coefficient using baseline serum creatinine. 9) Patients with known malignancies and active inflammatory diseases or without available hs-CRP were excluded, and then all remaining patients were divided into three groups according to the preprocedural hs-CRP level (< 0.05, 0.05-0.17, and > 0.17 mg/dL).
Data on demographics, coronary risk factors, and medications were collected from our institutional database. Blood samples were collected in the early morning after overnight fasting, and blood pressure (BP) was measured on admission. Patients with BP of > 140/90 mmHg or those who were receiving antihypertensive drugs were regarded as hypertensive. Dyslipidemia was defined as a low-density lipoprotein cholesterol (LDL-C) level of " 140 mg/dL, a high-density lipoprotein cholesterol (HDL-C) level of !40 mg/dL, a triglyceride (TG) level of "150 mg/dL, or current treatment with statins and/or lipidlowering agents. 10) Diabetes mellitus was defined as either a hemoglobin A1c level of "6.5% or medication with insulin or oral hypoglycemic drugs. Written informed consent was obtained from all patients prior to the PCI. This study proceeded in accordance with the Declaration of Helsinki and was approved by our institutional review board. Primary endpoints: The primary endpoint comprised major adverse cardiac events (MACE), which was defined as a composite of all-cause death and nonfatal myocardial infarction (MI). Clinical follow-up included a review of medical charts, telephone contact, and questionnaires sent to the patients or their families. Mortality data were collected from the medical records of the patients who died or were treated at our institution; the details and causes of death were requested from the other hospitals to which the patients were admitted. MI was defined as evidence of myocardial necrosis in a clinical setting that was consistent with myocardial ischemia. Statistical analysis: Quantitative data were presented as the mean ± standard deviation or median (interquartile range, IQR), and categorical variables were presented as frequencies. Patients were assigned to tertiles according to the previously mentioned preprocedural hs-CRP values. Continuous variables across tertiles were compared using one-way analysis of variance or the Kruskal-Wallis test. Categorical variables were compared using the chi-squared test. Pearson's correlation coefficients were used to examine the relationships between log-transformed hs-CRP and other variables. The unadjusted cumulative event rates were estimated using Kaplan-Meier curves and were compared across tertiles. The effects of hs-CRP levels on the clinical outcomes after PCIs were determined using multivariate Cox proportional hazard regression analysis; hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for each factor. Variables that had P-values of < 0.05 in the univariate analyses were included in the multivariable analyses. The multivariable model was adjusted for age, gender, hypertension, diabetes mellitus, body mass index (BMI), use of statins, and left ventricular ejection fraction. Differences were considered statistically significant at P < 0.05. Statistical analyses were carried out using JMP version 12.0 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics: Of the 2,092 patients who underwent PCIs, preprocedural hs-CRP values were available for only 1,694 of them (81.0%). Patients with CKD (n = 541) were excluded (Figure 1 ). In the remaining 1,153 pa-hs-CRP AND MACE IN NON-CKD PATIENTS tients (55.1%), the median hs-CRP level was 0.09 mg/dL (IQR: 0.04-0.20 mg/dL). The clinical characteristics of the patients stratified by the tertiles of preprocedural hs-CRP are shown in Table I . Compared with the other patients, those with the highest hs-CRP level had the highest incidence of current smoking; highest baseline LDL-C, TG, fasting blood glucose, and BMI; and lowest HDL-C and serum albumin levels. In addition, the reference vessel diameter was larger in patients in the higher hs-CRP tertiles. The correlations of the log-transformed hs-CRP levels with BMI (r = 0.12, P < 0.001), LDL-C (r = 0.09, P = 0.001), and HDL-C (r = −0.14, P < 0.001) were significant, but those with age (P = 0.83) and eGFR (P = 0.98) were not significant. Clinical outcomes: The median follow-up period was 7.5 years (IQR: 4.9-9.8 years). In total, 128 MACE (frequency: 11.1%) were identified during the follow-up, including 100 deaths (8.7%) and 28 nonfatal MI cases (2.4%). Kaplan-Meier analysis showed that the cumulative incidences of MACE and all-cause death were highest in the highest tertile of hs-CRP (log-rank test, both P < 0.01, Figure 2 ). Table II shows the Cox proportional hazard analysis for MACE and all-cause death. In the unadjusted Cox model, the rates of MACE and all-cause death increased progressively with increasing hs-CRP (both P < 0.01 for trend). Even after adjusting for the other risk factors, these associations between the cardiac events and the hs-CRP tertiles remained. Patients in the highest hs-CRP tertile exhibited higher frequencies of MACE (HR: 1.92, 95% CI: 1.23-3.07; P = 0.004) and mortality (HR: 2.16, 95% CI: 1.32-3.64; P = 0.002), compared with those with in the lowest tertiles. Table III summarizes the findings of the multivariable Cox hazard regression analysis, which included hs-CRP as a continuous variable. Even after adjusting for the other covariates, higher hs-CRP levels were significantly associated with a higher incidence of MACE (HR: 1.10 per log hs-CRP 1 increase, 95% CI: 1.04-1.16; P = 0.0004) and all-cause death (HR: 1.14 per log hs-CRP 1 increase, 95% CI: 1.06-1.22; P = 0.0002).
Discussion
The major findings of the present report were as follows: (1) patients with preserved renal function and a high SHIMIZU, ET AL The adjusted-for variables were the age, gender, hypertension, diabetes mellitus, BMI, use of statins, and LVEF. CI indicates confidence interval; HR, hazard ratio; and MACE, major adverse cardiac events. preprocedural hs-CRP level (> 0.17 mg/dL) showed significantly higher incidences of MACE and all-cause death, compared with patients with lower preprocedural hs-CRP levels;
(2) even after adjusting for important covariates, a high preprocedural hs-CRP level was strongly associated with increased MACE and mortality in patients with no CKD who underwent PCIs. Therefore, we believe that predicting the risk of future cardiovascular events based on the preprocedural concentration of hs-CRP may be applicable to Japanese patients with preserved renal function. CKD is characterized by persistent low-grade inflammation. 11) Cytokines regulate the inflammatory response; some of their downstream effects are mediated by positive hs-CRP AND MACE IN NON-CKD PATIENTS acute-phase proteins, such as CRP, fibrinogen, and albumin. 12, 13) Tonelli et al. reported that a higher CRP level was independently associated with faster rates of kidney function loss in CKD. 14) Stuveling et al. reported that early inflammatory processes, which were estimated by hs-CRP related to high body fat, may predispose the kidney to glomerular-hyperfiltration-related renal function loss. 15) A high preprocedural hs-CRP level has long been an important issue among patients with CKD. Indeed, in our PCI registry, the median preprocedural hs-CRP level in patients who underwent PCIs was significantly higher in patients with CKD (0.13 mg/dL) than in those without CKD (0.09 mg/dL; P < 0.001). 16) However, the present study is the first to show the clinical significance of inflammation in patients with preliminary diagnoses of CKD and non-CKD.
A number of theories have been advanced to explain the link between the deterioration of the renal function and inflammation. One theory was that inflammationrelated renal dysfunction occurs through a reduction in nitric oxide synthase activity. 17) Another theory suggested that renal dysfunction and CRP are related through shared risk factors. Hypertension, obesity, and diabetes have been known to be strongly related to both systemic inflammation and renal dysfunction. 15) In addition, inflammation is a common feature of advanced CKD; however, studies on the biomarkers of acute-phase inflammation in patients with less advanced kidney disease are scarce.
Furthermore, the present study showed that hs-CRP may be a prognostic indicator in the Asian population. The median preprocedural hs-CRP level in this study (0.09 mg/dL) was much lower than that in western populations. 18) Arima et al. reported that hs-CRP levels were associated with future coronary events in a general Japanese population and demonstrated that the hs-CRP cut-off value for a high risk of future development of CAD was likely to be >0.1 mg/dL, which was much lower than that of western populations. 19) Choi et al. reported that, in an unselected cohort of Korean patients who underwent PCIs with drug-eluting stents, a combination of poor renal function and high hs-CRP was associated with a higher risk of cardiovascular events. 20) To the best of our knowledge, this is the first study evaluating the association between preprocedural hs-CRP concentrations and preserved renal function in Asian patients who underwent elective PCIs.
This study had several limitations. As a single-center, observational study on a small patient cohort, unknown confounding factors might have affected the outcomes, regardless of the analytical adjustments. The relatively small number of events may have contributed to the lack of statistically significant differences. Second, in some patients, high hs-CRP levels may have been related to infections. Information on the presence of active infections and sources of inflammation was unavailable in our study, although we generally avoided performing PCIs when patients were receiving treatment for active infections or malignant diseases. Finally, there were no available information on coronary artery plaques. Previous studies have shown an association between serum CRP levels and plaque burden or morphology, 21) so these data might be useful.
Conclusions
Elevated preprocedural serum hs-CRP levels were associated with long-term clinical outcomes after PCIs in patients with preserved renal function. Consequently, hs-CRP could be a useful and strong predictor for long-term risk assessments in Japanese patients with no CKD undergoing PCIs.
